ATHA

Athira Pharma

ATHA

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)97%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ATHA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Dec 22

Athira Pharma, Inc. (ATHA) has abandoned its old path to develop a "ready-to-go" Phase 3 breast cancer drug, with a market opportunity of $15.9 billion.
The company's previous CEO was involved in a scandal regarding faked data, leading to their resignation.
The current price of ATHA is $6.75.

Generated by AI

Sentiment

Of the messages about ATHA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	82.63% -4.44
Bearish	—	—	—	17.37% +4.44

Bullish· Dec 19

ATHA stock has been identified as a potential buy before Friday at 3 pm, with the author predicting a significant market movement.
ATHA is expected to experience a massive volume spike, with 60M+ shares traded, and is considered a low-liquidity ticker that has been consolidating after a huge bearish gap down.
ATHA has received good news, including a new cancer program and funding, which could lead to a significant price increase, potentially reaching $10.50 before entering a gap.

Bearish· Dec 18

$ATHA is diluting by 300% due to potential future share issuances, which could negatively impact the stock.
$ATHA's recent price drop to $6.77 and large red candle formation indicate continued declines towards $6.
$ATHA's poor prospects are highlighted by its history of reversing splits and being on the verge of delisting from the Nasdaq two months ago.

Generated by AI

Topics

Of the messages about ATHA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	0%	0%	12.93%
Announcements	—	100%	100%	54.35%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	1.58%
Technical Analysis	—	0%	0%	31.13%

Announcements· Dec 18

Athira Pharma, Inc. (ATHA) announced an exclusive license to lasofoxifene Phase 3 development program for metastatic breast cancer candidate and a financing for up to $236 million.
The company will receive upfront financing of $90 million to fund development, with an additional potential financing of $146 million via the license agreement.
Athira Pharma's stock price surged 63% pre-market on the news, with the company's market capitalization increasing significantly.

Controversies· Jun 29

Athira Pharma, Inc. (ATHA) is facing multiple class action lawsuits due to allegations of misrepresentations in its IPO registration statement and image manipulation claims.
The lawsuits were filed by several law firms, including Keller Rohrback, Longman Law, P.C., Bragar Eagel & Squire, P.C., and Block & Leviton LLP, among others.
The allegations against Athira Pharma's CEO and underwriters of the IPO are being investigated, with some law firms encouraging investors to contact them to discuss potential securities fraud cases.

Technical Analysis· Dec 18

$ATHA has shown high relative strength and is a top watch going into open, with a range to $8.30+ if it can hold over earlier resistance.
The stock has a small float, good catalyst, and price is holding the post-gap base, with a structure that is fine as long as it stays above the low 7s.
Monitoring $ATHA for a scalp play on a break above 6.50, with a potential spike higher from open if it gaps and opens relatively close to highs.

Generated by AI

Community

Of the messages about ATHA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	60.71%	60.71%	9.86%
Newcomers	100%	39.29%	39.29%	90.14%

Regulars· Nov 1

The regulars are holding their position in Athira Pharma, Inc. (ATHA) despite a 52-week low, citing the company's strong cash position ($2.60 per share) as a reason to stay in.
The stock is experiencing a gap, with trading starting around $0.70, and is seeing record volume.
Perceptive Advisors LLC, a major shareholder, has filed a SC 13D/A, indicating a significant increase in their holdings, with ATHA stock price rising 25.6% pre-filing.

Newcomers· Dec 19

The acquisition of global rights to lasofoxifene, a SERM, for a registrational Phase 3 trial in ESR1-mutant metastatic breast cancer could be registrational and is supported by $90M upfront and up to $146M in warrant-linked financing.
Athira Pharma's stock is considered a low liquidity ticker with a consolidating pattern after a huge bearish gap down, and recent news and funding should benefit the stock.
The stock has experienced a violent breakout from a long base on massive volume, with an overextended short-term RSI, indicating a potentially strong price movement.

Generated by AI

Also Discussed

Investors talking about ATHA also mention

#	Name	Attention
1	Annovis Bio, Inc.ANVS	0%0
2	AMC Robotics CorporationAMCI	0%0
3	BioVie Inc.BIVI	0%0
4	Cassava Sciences Inc.SAVA	0%new
5	Alector Inc.ALEC	0%new
6	Highway Holdings LimitedHIHO	0%0
7	ANGN - Angion Biomedica Corp.	——
8	RAPT - RAPT Therapeutics, Inc.	——
9	Gemini Therapeutics, Inc.GMTX	0%0
10	Processa Pharmaceuticals Inc.PCSA	0%0

Athira Pharma, Inc.

Location

Social

What share of all stock conversation is about ATHA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Dec 22

Athira Pharma, Inc. (ATHA) has abandoned its old path to develop a "ready-to-go" Phase 3 breast cancer drug, with a market opportunity of $15.9 billion.
The company's previous CEO was involved in a scandal regarding faked data, leading to their resignation.
The current price of ATHA is $6.75.

Generated by AI

Sentiment

Of the messages about ATHA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	82.63% -4.44
Bearish	—	—	—	17.37% +4.44

Bullish· Dec 19

ATHA stock has been identified as a potential buy before Friday at 3 pm, with the author predicting a significant market movement.
ATHA is expected to experience a massive volume spike, with 60M+ shares traded, and is considered a low-liquidity ticker that has been consolidating after a huge bearish gap down.
ATHA has received good news, including a new cancer program and funding, which could lead to a significant price increase, potentially reaching $10.50 before entering a gap.

Bearish· Dec 18

$ATHA is diluting by 300% due to potential future share issuances, which could negatively impact the stock.
$ATHA's recent price drop to $6.77 and large red candle formation indicate continued declines towards $6.
$ATHA's poor prospects are highlighted by its history of reversing splits and being on the verge of delisting from the Nasdaq two months ago.

Generated by AI

Topics

Of the messages about ATHA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	0%	0%	12.93%
Announcements	—	100%	100%	54.35%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	1.58%
Technical Analysis	—	0%	0%	31.13%

Announcements· Dec 18

Athira Pharma, Inc. (ATHA) announced an exclusive license to lasofoxifene Phase 3 development program for metastatic breast cancer candidate and a financing for up to $236 million.
The company will receive upfront financing of $90 million to fund development, with an additional potential financing of $146 million via the license agreement.
Athira Pharma's stock price surged 63% pre-market on the news, with the company's market capitalization increasing significantly.

Controversies· Jun 29

Athira Pharma, Inc. (ATHA) is facing multiple class action lawsuits due to allegations of misrepresentations in its IPO registration statement and image manipulation claims.
The lawsuits were filed by several law firms, including Keller Rohrback, Longman Law, P.C., Bragar Eagel & Squire, P.C., and Block & Leviton LLP, among others.
The allegations against Athira Pharma's CEO and underwriters of the IPO are being investigated, with some law firms encouraging investors to contact them to discuss potential securities fraud cases.

Technical Analysis· Dec 18

$ATHA has shown high relative strength and is a top watch going into open, with a range to $8.30+ if it can hold over earlier resistance.
The stock has a small float, good catalyst, and price is holding the post-gap base, with a structure that is fine as long as it stays above the low 7s.
Monitoring $ATHA for a scalp play on a break above 6.50, with a potential spike higher from open if it gaps and opens relatively close to highs.

Generated by AI

Community

Of the messages about ATHA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	60.71%	60.71%	9.86%
Newcomers	100%	39.29%	39.29%	90.14%

Regulars· Nov 1

The regulars are holding their position in Athira Pharma, Inc. (ATHA) despite a 52-week low, citing the company's strong cash position ($2.60 per share) as a reason to stay in.
The stock is experiencing a gap, with trading starting around $0.70, and is seeing record volume.
Perceptive Advisors LLC, a major shareholder, has filed a SC 13D/A, indicating a significant increase in their holdings, with ATHA stock price rising 25.6% pre-filing.

Newcomers· Dec 19

The acquisition of global rights to lasofoxifene, a SERM, for a registrational Phase 3 trial in ESR1-mutant metastatic breast cancer could be registrational and is supported by $90M upfront and up to $146M in warrant-linked financing.
Athira Pharma's stock is considered a low liquidity ticker with a consolidating pattern after a huge bearish gap down, and recent news and funding should benefit the stock.
The stock has experienced a violent breakout from a long base on massive volume, with an overextended short-term RSI, indicating a potentially strong price movement.

Generated by AI

Athira Pharma

Social

Dec 22

Sentiment

Bullish· Dec 19

Bearish· Dec 18

Topics

Announcements· Dec 18

Controversies· Jun 29

Technical Analysis· Dec 18

Community

Regulars· Nov 1

Newcomers· Dec 19

Also Discussed

Athira Pharma, Inc.

Company Information

Location

Social

Dec 22

Sentiment

Bullish· Dec 19

Bearish· Dec 18

Topics

Announcements· Dec 18

Controversies· Jun 29

Technical Analysis· Dec 18

Community

Regulars· Nov 1

Newcomers· Dec 19

Also Discussed